Cargando…

Transcatheter aortic valve replacement same-day discharge for selected patients: a case series

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has resulted in drastic changes to the practice of medicine, requiring healthcare systems to find solutions to reduce the risk of infection. Using a case series, we propose a protocol for same-day discharge (SDD) for selected patients unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Devesh, Tahir, Muhammad Waqas, Chowdhury, Medhat, Ali, Hammad, Buttar, Rupinder, Abtahian, Farhad, Bhatt, Deepak L, Depta, Jeremiah P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Plant Biologists 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873812/
https://www.ncbi.nlm.nih.gov/pubmed/33598624
http://dx.doi.org/10.1093/ehjcr/ytaa556
Descripción
Sumario:BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has resulted in drastic changes to the practice of medicine, requiring healthcare systems to find solutions to reduce the risk of infection. Using a case series, we propose a protocol for same-day discharge (SDD) for selected patients undergoing transcatheter aortic valve replacement (TAVR) using real-time remote cardiac monitoring. Six patients with severe symptomatic aortic stenosis underwent TAVR and were discharged on the same day. CASE SUMMARY: Six patients with symptomatic severe native or bioprosthetic aortic valve stenosis underwent a successful transfemoral TAVR using standard procedures, including the use of rapid atrial pacing to assess the need for permanent pacemaker implantation. Following TAVR, patients were monitored on telemetry in the recovery area for 3 h, ambulated to assess vascular access stability, and discharged with real-time remote cardiac monitoring if no new conduction abnormality was observed. The patients were seen by tele-visits within 2 days and 2 weeks after discharge. DISCUSSION: Amidst the COVID-19 pandemic, SDD following successful transfemoral TAVR may be feasible for selected patients and reduce potential COVID-19 exposure.